The oncogenic fusion gene BCR-ABL is one of the crucial molecular biological features that are responsible for the pathogenesis and therapeutic resistance of CML patients and activates diverse signaling pathways related to the proliferation and survival of tumor cells, such as the JAK/STAT pathway.123. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.